Table 5.

Prevalence of lean individuals meeting criteria proposed for metabolic associated fatty liver disease (MAFLD) in cohort I (A) and cohort II (B)

A	Lean w/o NAFLD (n = 892)	Lean NAFLD (n = 205)	P
DM	45 (5.1%)	25 (12.3%)	<0.001
	n = 847	n = 180
WC ≥102/88 cm	104 (12.3%)	42 (23.3%)	<0.001
BP ≥130/85 mm Hga	399 (47.1%)	106 (58.9%)	0.004
Triglycerides ≥150 mg/dL	63 (7.4%)	38 (21.1%)	<0.001
HDL-C <40/50 mg/dLa	106 (12.5%)	40 (22.2%)	0.001
Prediabetes	342 (40.4%)	103 (57.2%)	<0.001
HOMA-IR ≥2.5	52 (6.1%)	24 (13.3%)	0.001
hsCRP >0.2 mg/L	83 (9.8%)	35 (19.4%)	<0.001
MAFLD	—	n = 143 (69.8%)	—

B	Lean w/o NAFLD (n = 254)	Lean NAFLD (n = 169)	P
DM	7 (2.8%)	12 (7.1%)	0.035
	n = 247	n = 157
WC ≥102/88 cm	22 (8.9%)	24 (15.3%)	0.049
BP ≥130/85 mm Hga	144 (58.3%)	115 (73.2%)	0.002
Triglycerides ≥150 mg/dL	13 (5.3%)	30 (19.1%)	<0.001
HDL-C <40/50 mg/dLa	23 (9.3%)	23 (14.6%)	0.100
Prediabetes	56 (22.7%)	58 (36.9%)	0.002
HOMA-IR ≥2.5	4 (1.6%)	15 (9.6%)	<0.001
hsCRP >0.2 mg/L	23 (9.3%)	13 (8.3%)	0.737
MAFLD	—	88 (52.1%)	—

BP, blood pressure; DM, diabetes mellitus; HOMA-IR, Homeostasis Model Assessment for Insulin Resistance; NAFLD, nonalcoholic fatty liver disease; WC, waist circumference.

^aOr specific treatment.